Objective RAPID3 is a patient reported, composite index, designed for feasibility in clinical care. RAPID3 was developed in rheumatoid arthritis, but has been found useful in many rheumatic diseases. We analysed RAPID3 in patients with psoriatic arthritis (PsA).
Methods
Post-hoc analyses were performed on two independent datasets, the tight control of PsA (TICOPA) trial, and the long-term outcome in PsA study (LOPAS II), an observational cohort. RAPID3 (0-30) is calculated as the total of three 0-10 scores for HAQ-DI (recalculated from 0-3), pain visual analog scale (VAS), and global VAS. Data were compared to the PsA disease activity score (PASDAS) and disease activity in psoriatic arthritis (DAPSA) and other available clinical measures, according to Spearman correlation coefficients, standardised response mean (SRM), standard error of the mean (SEM), smallest detectible difference (SDD), minimally important difference (MID in patients who improved) and receiver-operating characteristic (ROC) curves. RAPID3 remission was compared to criteria for both standard minimal disease activity (MDA) and very low disease activity (VLDA).
Results
RAPID3 was correlated significantly with PASDAS in TICOPA (r=0.79, p<0.01) and with DAPSA in LOPAS (rho=0.59, p<0.01) and with most other measures in both datasets. RAPID3 discriminated between tight control and standard care in TICOPA at 48 weeks at levels comparable to DAPSA and the PASDAS (p<0.01). RAPID3 remission discriminated treatment groups in TICOPA intermediate between MDA and VLDA criteria.
Conclusion 4 RAPID3 appears comparably informative to PASDAS and DAPSA in PsA, with greater feasibility for routine clinical care.
Significance and Innovation
 RAPID3 correlates well with more comprehensive PsA-specific outcome measures, both those assessing arthritis (DAPSA) and global disease activity (PASDAS)  RAPID3 can differentiate treatment groups in the TICOPA clinical trial.  A modified RAPID3 including a skin VAS was not clearly superior in performance but levels of skin disease were low in the datasets used.  RAPID3 remission correlates well at the individual patient level with other remission measures but physical examination is still required for optimal clinical decision making. RAPID3 was developed initially in RA, but subsequently has been found informative in axial spondyloarthritis(4-7), osteoarthritis(8), gout(9) systemic lupus erythematosus(10) and other arthritides (9, (11) (12) (13) . Whilst the primary goal for RAPID3 was feasibility in routine care to provide quantitative data for prognosis, management and outcomes, scores generally have been found quite comparable to more elaborate disease-specific indices (14) .
This study assessed the potential value of RAPID3 to depict clinical status compared to PASDAS, DAPSA, and other measures in two datasets, the tight control of PsA (TICOPA) study, a clinical trial, and the long term outcome of PsA study (LOPAS II), an observational cohort.
An important consideration that RAPID3 may not address the dermatological aspects of PsA effectively was analysed using a modified RAPID3Ps, which included a fourth item, a VAS scale for skin disease activity that could be added to the original RAPID3.
Materials and Methods
Data. Post-hoc analyses were performed on two independent datasets to study the value of RAPID3 in PsA. First, we analysed data from the tight control of PsA (TICOPA) clinical trial (ClinicalTrials.gov NCT01106079, ISCRCTN30147736), to assess its performance in a controlled trial setting. Second, we used data from the long-term outcomes in PsA study (LOPAS II) to assess its performance in an observational cohort setting (15) .
TICOPA trial. The TICOPA trial is a UK multicentre randomised controlled trial, in which 206 adults with early psoriatic arthritis were randomly assigned on a 1:1 ratio either to tight control with a step-up regimen aiming for minimal disease activity using methotrexate, combination disease-modifying anti-rheumatic drugs (DMARDs) and anti-tumour necrosis factor drugs as required or to standard care (16) . In the TICOPA dataset, the PsA disease activity score (PASDAS) was used as the gold standard comparator, as this composite measure addresses all aspects of psoriatic disease (17) . Differences between treatment groups according to RAPID3, PASDAS and other PsA measures were compared.
LOPAS II observational cohort. LOPAS II is a prospective, multicentre observational cohort study to investigate the effect of conventional synthetic disease modifying anti rheumatic drugs (csDMARD) and anti-Tumour Necrosis Factor inhibitors (anti-TNF) on clinical and patient reported outcomes among PsA patients of any age and disease duration who fulfilled the classification for psoriatic arthritis (CASPAR) criteria (18) and were being commenced on csDMARD or anti-TNF as part of routine clinical care. In the LOPAS study, analyses were undertaken on participants with complete data at baseline and three months follow up. The Disease Activity in Psoriatic Arthritis (DAPSA) was used as a composite measure of articular disease (calculated from the 66/ 68 tender and swollen joints count, c reactive protein, patient global assessment and pain visual analogue scales) (19) . The required items for MDA and PASDAS were not all available in this dataset. The range for RAPID3 is 0-30 and severity categories have been defined for RA: ≤3 for remission, 3.1-6.0 for low, 6.1-12.0 for moderate, and >12 for high severity (21) . These potential categories were studied in comparison with other remission and low disease categories from PsA specific measures, at both group and individual levels. RAPID3
remission was compared to both the standard Minimal Disease Activity (MDA) criteria (22) and the very low disease activity (VLDA) criteria (23), which were developed specifically for PsA and have been shown to correlate well with other disease activity measures (24, 25) in
PsA. MDA also is associated with physician and patient opinion of low disease activity using anchor questions (23) , and has prognostic value for better functional outcome and lower rates of radiographic damage (26) . The MDA criteria for PsA require meeting 5 of 7 cutpoints in 7 measures: HAQ≤0.5, patient global VAS≤20mm, patient pain VAS≤15mm (the three RAPID measures, though at different cut-points); tender joint count (TJC)≤1; swollen joint count (SJC) ≤1; enthesitis count≤1 and psoriasis area and severity index (PASI) ≤1 or body surface area (BSA) ≤3 (22) . To meet VLDA criteria, all seven cut points must be met (23) . This endpoint has been investigated in view of the emphasis on remission as the ideal target for treatment (27) ; preliminary validation has indicated that it is a very stringent measure (23) . A more stringent method to assess remission based on RAPID3, with addition of whether a patient has 0 or1 vs >1 swollen joint (RAPID3SJC1) (28, 29) RAPID3 was highly discriminant of change in the tight control vs standard treatment groups (Table 1) . (t value -3.43, p<0.01) and superior to each individual measure. Patient-reported measures were more discriminant than joint counts (Table 1) . RAPID3 also was similar in discrimination to the disease activity in PsA (DAPSA) score, but slightly less than PASDAS (table   2) . When plotting mean scores for both PASDAS and RAPID3 in the TICOPA trial, similar responses are seen at each timepoint (figure S1).
The proportions of patients who were classified as in remission according to RAPID3 and RAPID3SJC1 lies between MDA and VLDA ( Correlation with clinical joint count and CRP was lower: tender joint count (0.39), swollen joint count (0.21), CRP (0.17). No significant difference was seen between the response to treatment (within each independent treatment group) according to RAPID3 or DAPSA for either the TNF (p= 0.76) or DMARD (p=0.09) groups ( Figure S1 ).
RAPID3 was responsive according to the mean change, SEM, SRM and SDD during follow up (Table 3 ). The MID for improvement using the anchor method for the RAPID3 was -8.1 (sd 5.9) and DAPSA -27.9 (sd 23.7). The MID using the ROC method (figure 3) for the RAPID3 was -5.1 (AUC 0.84) and DAPSA -16.7 (AUC 0.75). Using initiation of treatment (baseline visit) as a gold standard for active disease, only a small number of patients were potentially misclassified as being in remission or low disease activity by either score: DAPSA (2.3%) and RAPID3 (5%).
RAPID3 was correlated significantly with the EQ5D, Joint VAS and FACIT fatigue, but at lower levels with clinical joint counts and the CRP. This finding highlights some disconnect between physician and patient reported outcomes.
Discussion
These analyses indicate that RAPID3 and RAPID3Ps show good responsiveness and discrimination in PsA. In the TICOPA dataset, RAPID3 is correlated highly with the PASDAS score and is more discriminative than individual measures and the DAPSA score. In the LOPAS dataset, RAPID3 is correlated significantly with the DAPSA and had similar responsiveness.
We also report an estimate of the MID for improvement and smallest detectable difference for the RAPID3 in PsA.
The RAPID3 score is a generic tool developed to assess patient status quantitatively in clinical practice. It was developed in RA and has been found of value in many rheumatic conditions, including spondyloarthritis(4-7), osteoarthritis(8), gout(9) systemic lupus erythematosus (10) and other arthritides (9, (11) (12) (13) . However, in PsA, in addition to the musculoskeletal manifestations, most patients also have skin psoriasis. In these analyses, adding a skin disease activity VAS to create the RAPID3Ps did not show a meaningful advantage over the established RAPID3 score. This may be anticipated since RAPID3 measures constitute 3 of 4 in RAPID3Ps, skin involvement was mild in these cohorts and it may be captured at least in part in the patient global assessment. The use of the HAQ as a measure of disease activity in PsA may be questioned. The HAQ primarily assesses upper limb (hand) function and was developed in RA. PsA has different musculoskeletal manifestations (enthesitis/ dactylitis, differing joint distributions such as large joint monoarthritis). Furthermore it has been suggested that HAQ function scores become more influenced by damage than activity in established disease, potentially limiting responsiveness (31) . However, despite these theoretical concerns we found RAPID3 to be sensitive to change and discriminative in early disease (TICOPA) and later disease (LOPAS), in keeping with other studies showing responsiveness of HAQ even in established disease (32, 33) .
Several methodological limitations are recognized in interpreting the finding of this study. The RAPID3 was calculated from existing outcome measures collected within the two studies.
Therefore the HAQ-DI was used instead of the MD-HAQ and VAS scales for pain and global disease activity were used rather than the NRS in the RAPID3 tool. We believe from previous studies that these are comparable but future research with the specific RAPID3 tool is required. To maximise feasibility in clinical practice, the use of a standard tool (RAPID3) across all diseases appears desirable. However, it must be noted that these patients were all recruited from rheumatology clinics and the average levels of skin disease were very low (TICOPA: median PASI 2.6, LOPAS II: median Dermatology Quality of Life Index -DLQI 2.0 and skin VAS 30.5/100). The absence of a skin specific measure may limit performance in a population with substantial skin disease. There were also a few patients in RAPID3 remission who had signs of active disease on clinical assessment. Thus, clinical assessment, in addition to the RAPID3 or any index, is required in all patients. Unfortunately there was little change in radiographic damage over the 48 week period of the TICOPA study and radiographs were not routinely performed in the LOPAS study therefore the relationship between RAPID3 and radiographic damage has not been explored in this paper.
We have not analysed possible influence of contextual factors or comorbidities on RAPID3.
Such contextual factors as fibromyalgia are known to impact all rheumatology indices, which necessarily include at least one patient-reported measure independent of disease activity. (21, 35) .
We report data from two independent datasets examining the responsiveness and discrimination of RAPID3 in PsA. We also report data suggesting the addition of a skin assessment does not improve sensitivity to change in these particular cohorts. We also report an estimate of the MID for improvement in PsA. Taken together these data support the value and validity of RAPID3 as a feasible and sensitive measure of disease activity in PsA. DAPSA -disease activity in psoriatic arthritis, ES -effect size, PASDAS -PsA disease activity score, Phys -physician, Pt -patient, RAPID3 -routine assessment of patient index data 3, TJC -tender joint count, SJC -swollen joint count, SRM -standardised response mean, VAS -visual analogue score DAPSA -disease activity in psoriatic arthritis, MDA -minimal disease activity, RAPID3 -routine assessment of patient index data 3, PASDAS -psoriatic arthritis disease activity score, StdCstandard care, TC -tight control, TICOPA -tight control of psoriatic arthritis, VLDA -very low disease activity 
